Premium
Hepatitis C virus–infected kidney waitlist patients: Treat now or treat later?
Author(s) -
Kiberd B. A.,
Doucette K.,
Vinson A. J.,
Tennankore K. K.
Publication year - 2018
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14891
Subject(s) - medicine , hepatitis c virus , hepatitis c , transplantation , kidney transplantation , antiviral therapy , incidence (geometry) , intensive care medicine , surgery , virus , immunology , chronic hepatitis , physics , optics
Currently many but not all centers transplant hepatitis C virus (HCV) viremic positive (+) donor kidneys into HCV + recipients. Directed donation of HCV + organs reduces the wait time to transplantation for HCV + patients. Direct‐acting antiviral ( DAA ) therapy can cure HCV in virtually all who are infected. Some have suggested that treatment of HCV + waitlisted patients be deferred with the hope that earlier transplantation will provide better outcomes than early DAA therapy. However, there are not enough organs to guarantee prompt transplantation for the current waitlist of infected candidates. A Markov medical decision analysis model was created to compare the overall outcomes of delayed DAA therapy (Option 1) to immediate DAA therapy (Option 2) in waitlisted HCV + patients. Option 1 patients were modeled to be transplanted 1 year earlier, with a higher cumulative transplant incidence (54% at 5 years post‐listing vs 45% for Option 2). Despite this, Option 2 provided 0.43 (95% confidence interval [CI ] 0.38–0.49) more life years than Option 1. However, Option 1 was preferred for regions with much greater access to HCV + organs or in patients with very low HCV +‐associated mortality. The best option from an individual patient's perspective will differ by region and candidate.